0001213900-24-103469.txt : 20241127 0001213900-24-103469.hdr.sgml : 20241127 20241127161537 ACCESSION NUMBER: 0001213900-24-103469 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20241125 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20241127 DATE AS OF CHANGE: 20241127 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pluri Inc. CENTRAL INDEX KEY: 0001158780 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980351734 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31392 FILM NUMBER: 241511388 BUSINESS ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 BUSINESS PHONE: 972-74-710-7171 MAIL ADDRESS: STREET 1: MATAM ADVANCED TECHNOLOGY PARK STREET 2: BUILDING NO. 5 CITY: HAIFA STATE: L3 ZIP: 3508409 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM THERAPEUTICS INC DATE OF NAME CHANGE: 20071228 FORMER COMPANY: FORMER CONFORMED NAME: PLURISTEM LIFE SYSTEMS INC DATE OF NAME CHANGE: 20030701 FORMER COMPANY: FORMER CONFORMED NAME: AI SOFTWARE INC DATE OF NAME CHANGE: 20010906 8-K 1 ea0222850-8k_pluri.htm CURRENT REPORT
false 0001158780 0001158780 2024-11-25 2024-11-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): November 27, 2024 (November 25, 2024)

 

PLURI INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   001-31392   98-0351734
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

MATAM Advanced Technology Park     
Building No. 5    
Haifa, Israel   3508409
(Address of Principal Executive Offices)   (Zip Code)

 

011 972 74 710 7171

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, par value $0.00001 per share   PLUR   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On November 25, 2024, Pluri Inc., or Pluri or the Company, received a deficiency letter, or the Nasdaq Letter, from the Listing Qualifications Department of The Nasdaq Stock Market LLC, or Nasdaq, notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market, or the Stockholders’ Equity Requirement, nor is it in compliance with either of the alternative listing standards, market value of listed securities of at least $35 million or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years.

 

Pursuant to the Nasdaq Letter, the Company has 45 calendar days from the date of the Nasdaq Letter to submit a plan to regain compliance and the Company intends to submit such a plan during this period. If it accepts the plan, Nasdaq can grant an extension of up to 180 calendar days from the date of the Nasdaq Letter to evidence compliance. In the event the plan is not accepted by Nasdaq, or in the event the plan is accepted and the 180-day extension period granted but the Company fails to regain compliance within such plan period, the Company would have the right to a hearing before an independent panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.

 

The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. However, there can be no assurance that Nasdaq will grant the Company’s request for an extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing.

 

Neither the Nasdaq Letter nor the Company’s noncompliance have an immediate effect on the listing or trading of the Company’s common shares, which will continue to trade on The Nasdaq Capital Market under the symbol “PLUR”.

 

Forward Looking Statements

 

This Current Report on Form 8-K contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. For example, Pluri is using forward-looking statements when it discusses its potentially regaining compliance with Nasdaq’s continued listing requirements, and the timing and effect thereof. These forward-looking statements and their implications are based on the current expectations of the management of Pluri only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about Pluri: changes in technology and market requirements; Pluri may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, its technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluri reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PLURI INC.
   
Date: November 27, 2024 By: /s/ Liat Zalts
  Name:  Liat Zalts
  Title: Chief Financial Officer

 

 

2

 

 

EX-101.SCH 2 plur-20241125.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 plur-20241125_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 plur-20241125_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover
Nov. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 25, 2024
Entity File Number 001-31392
Entity Registrant Name PLURI INC.
Entity Central Index Key 0001158780
Entity Tax Identification Number 98-0351734
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One MATAM Advanced Technology Park
Entity Address, Address Line Two Building No. 5
Entity Address, City or Town Haifa
Entity Address, Country IL
Entity Address, Postal Zip Code 3508409
City Area Code 011
Local Phone Number 972 74 710 7171
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, par value $0.00001 per share
Trading Symbol PLUR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

UFJQ"(6,P$ "(" / " 680 !X;"]W M;W)K8F]O:RYX;6Q02P$"% ,4 " #R@7M9)!Z;HJT #X 0 &@ M @ '&$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #R@7M999!YDAD! #/ P $P @ &K$@ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #U$P ! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pluri-biotech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0222850-8k_pluri.htm plur-20241125.xsd plur-20241125_lab.xml plur-20241125_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0222850-8k_pluri.htm": { "nsprefix": "PLUR", "nsuri": "http://pluri-biotech.com/20241125", "dts": { "inline": { "local": [ "ea0222850-8k_pluri.htm" ] }, "schema": { "local": [ "plur-20241125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "plur-20241125_lab.xml" ] }, "presentationLink": { "local": [ "plur-20241125_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://pluri-biotech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-11-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0222850-8k_pluri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-11-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0222850-8k_pluri.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://pluri-biotech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001213900-24-103469-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-103469-xbrl.zip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end XML 15 ea0222850-8k_pluri_htm.xml IDEA: XBRL DOCUMENT 0001158780 2024-11-25 2024-11-25 iso4217:USD shares iso4217:USD shares false 0001158780 8-K 2024-11-25 PLURI INC. NV 001-31392 98-0351734 MATAM Advanced Technology Park Building No. 5 Haifa IL 3508409 011 972 74 710 7171 false false false false Common Shares, par value $0.00001 per share PLUR NASDAQ false